Theradaptive

Theradaptive is a private, preclinical-stage biotech founded in 2015, leveraging a proprietary protein engineering platform to overcome a central challenge in regenerative medicine: the precise and sustained local delivery of therapeutics. By engineering proteins to bind with high affinity to specific materials, the company aims to enhance efficacy and reduce systemic side effects across a range of clinical applications, with a lead focus on spinal fusion and orthopedic repair. The technology has demonstrated superiority over standard of care in multiple preclinical studies conducted at leading institutions, positioning the company to potentially redefine therapeutic delivery in surgery and beyond.

Proprietary computational and in vitro protein engineering platform that creates material-binding variants of recombinant proteins. These variants retain biological function but bind with high affinity to implants, devices, or injectable carriers, enabling precise, localized, and long-term therapeutic delivery.

Theradaptive competes in the regenerative medicine and targeted delivery space with large orthobiologics companies (Medtronic, Stryker), BMP-2 providers, and numerous startups developing growth factor delivery systems. Its differentiation lies in the simplicity of its one-step protein coating and the precision of delivery enabled by its novel engineered proteins.